Non-alcoholic fatty liver disease affects 64 million people in the United States, but, currently, there is not a non-invasive method to measure treatment response in fibrotic liver disease.1 As the hepatology industry continues to search for treatments that may one day cure fibrotic disease in the liver, there is an important hurdle that has yet […]

The agreement outlines a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 worldwide, once approved by regulatory authorities. COVAXX is currently developing UB-612 through a high precision, synthetic peptide platform that activates both B-cell and T-cell arms. The investigational vaccine has been manufactured to replicate […]

When Japan’s landmark regenerative medicine legislation took effect in 2014, it opened an entirely new market for biotech innovators. Athersys, a leader in regenerative medicine, seized the opportunity. Athersys’s MultiStem® cell therapy is in Phase III clinical trials in the U.S., and with Japanese partner Healios K.K. in Japan, to treat ischemic stroke and acute […]